VRTX vs GILD
VRTX and GILD side by side — valuation & fundamentals (public data).
Key statistics
| Metric | VRTXVERTEX PHARMACEUTICALS INC / MA | GILDGILEAD SCIENCES, INC. |
|---|---|---|
| Market cap | $128.59B | $186.46B |
| P/E (TTM) | 29.5 | 22.2 |
| P/B | 6.35 | 15.76 |
| P/S | 10.7x | 6.3x |
| Dividend yield | — | 2.15% |
| Revenue | $12.59B(TTM) | $30.46B(TTM) |
| Revenue growth (YoY) | 8.9% | 2.4% |
| Net income | $4.41B(TTM) | -$3.24B(TTM) |
| Earnings growth (YoY) | 838.1% | 1672.9% |
| EPS, diluted | $17.17(TTM) | $-2.65(TTM) |
| EBIT margin | 34.8% | 34.0% |
| ROE | 19.5% | 71.9% |
| ROIC | 25.0% | 26.7% |
| 1y total return | +30.9% | +35.1% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: VRTX frente a GILD
| Métrica | VRTX | GILD |
|---|---|---|
| Valor final | $62.8K | $26.2K |
| Retorno total | +528.2% | +161.6% |
| CAGR | +19.4% | +9.8% |
| Volatilidad | 32.7% | 25.6% |
| Sharpe | 0.58 | 0.33 |
| Sortino | 0.86 | 0.49 |
| Caída máxima | -41.6% | -30.5% |
Basado en 2600 días de negociación comunes, 2016-05-17 → 2026-09-18 · tasa libre de riesgo 4.12% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)